CTOs on the Move

Bellicum

www.bellicum.com

 
Bellicum Pharmaceuticals, located near the Houston Medical Center, is a clinical stage biopharmaceutical company focused on discovering and developing novel cellular immunotherapies for various forms of cancer, including both hematological and solid tumors, as well as orphan inherited blood disorders. We are developing next-generation product candidates in some of the most important areas of cellular immunotherapy, including hematopoietic stem cell transplantation (HSCT) and CAR T cell therapy. We are dedicated to creating an exceptional work environment and are passionate about working to provide innovative new treatment options that can improve health and save lives.
  • Number of Employees: 100-250
  • Annual Revenue: $1-10 Million
  • www.bellicum.com
  • 2130 West Holcombe Boulevard Suite 800
    Houston, TX USA 77030
  • Phone: 832.384.1100

Executives

Name Title Contact Details

Similar Companies

Amolyt Pharma

Amolyt Pharma is building on its team`s established expertise in therapeutic peptides development to deliver life-changing treatments to patients suffering from rare endocrine and metabolic diseases. Amolyt Pharma`s programs include AZP-3601, a parathyroid hormone analog, for the potential treatment of hypoparathyroidism and AZP-3404, a peptide with a new and unique mechanism of action, that may restore fat and glucose metabolism. The collaborative Amolyt Pharma team is well-equipped for upcoming milestones and for the adoption of additional programs as made possible by its global network in the field of endocrinology and with support from a strong syndicate of international investors.

XCELLENCE

XCELLENCE is a Tampa, FL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Bioray Pharma

Bioray Pharma is a Omaha, NE-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

ThromboGenics

ThromboGenics is an integrated biopharmaceutical company focused on developing and commercializing innovative ophthalmic and oncology medicines. The Company`s lead product, JETREA® (ocriplasmin), has been approved by the US FDA for the treatment of symptomatic VMA and was launched in January 2013. ThromboGenics signed a strategic partnership with Alcon, a division of Novartis, for the commercialization of JETREA® outside the United States. ThromboGenics is headquartered in Leuven, Belgium, and has offices in Iselin, NJ (US) and Dublin, Ireland. The Company is listed on the NYSE Euronext Brussels exchange under the symbol THR.

FamilyServiceRV

#Mentalhealth causes invisible wounds. Find strength, hope and how you can help heal others. Family Service of Roanoke Valley. https://t.co/57fyeIBthG